Article
Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs.
Breast (Edinburgh, Scotland) - 1 Oct 2018
Orditura M, Della Corte C M, Diana A, Ciaramella V, Franzese E, Famiglietti V, Panarese I, Franco R, Grimaldi A, Lombardi A, Caraglia M, Santoriello A, Procaccini E, Lieto E, Maiello E, De Vita F, Ciardiello F, Morgillo F
Abstract excerpt
Two inhibitors of phosphatidylinositol 3-kinase (PI3K) pathway taselisib, targeting the mutant PI3K-subunit-alpha (PI3KA) and ipatasertib, AKT-inhibitor, are currently under clinical investigation in breast cancer (BC) patients. We have previously demonstrated the anti-tumor efficacy of these anti-PI3K/AKT-inibitors in combination with anti-microtubule drugs in human BC cell lines, through a complete cytoskeleton...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.